Work

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Year: 2018

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-17-1922

Authors: Neil H. Segal, Aiwu R. He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal

Institutions: Memorial Sloan Kettering Cancer Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Stanford Medicine, Stanford University, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, Pfizer (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer, EMD Serono

OpenAlex ID: W2792883957

FWCI: 10.1

Cites: 28

Cited by: 263

Related to: 10